Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Cryo-Cell International's operating assets for the quarter that ended in Feb. 2026 was €49.06 Mil. Cryo-Cell International's operating liabilities for the quarter that ended in Feb. 2026 was €58.01 Mil. Cryo-Cell International's Total Assets for the quarter that ended in Nov. 2025 was €53.40 Mil. Therefore, Cryo-Cell International's scaled net operating assets (SNOA) for the quarter that ended in Feb. 2026 was -0.17.
Cryo-Cell International Scaled Net Operating Assets Related Terms
Cryo-Cell International Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Cryo-Cell International's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International Scaled Net Operating Assets Chart
STU:ZCY vs CCM, CDIX, EHSI: Scaled Net Operating Assets Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International Scaled Net Operating Assets vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of -0.17 mean?
Cryo-Cell International (STU:ZCY) has a Scaled Net Operating Assets of -0.17 as of Feb. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Cryo-Cell International and its competitors.
Is Cryo-Cell International's Scaled Net Operating Assets too high?
Cryo-Cell International's current Scaled Net Operating Assets is -0.17. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Scaled Net Operating Assets compare to CCM and CDIX?
Cryo-Cell International's Scaled Net Operating Assets of -0.17 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Healthcare Providers & Services company?
A good Scaled Net Operating Assets depends on the Healthcare Providers & Services industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Cryo-Cell International and its competitors. Cryo-Cell International's current Scaled Net Operating Assets is -0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (STU:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.67, compared to a current price of €2.80 — trading 40% below its estimated fair value. The current Scaled Net Operating Assets is -0.17. Cryo-Cell International's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current Scaled Net Operating Assets is -0.17 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €2.80 is trading 40% below its estimated GF Value™ of €4.67.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for STU:ZCY:
Scaled Net Operating Assets: -0.17
GF Value™: €4.67 vs. price of €2.80 (40% below fair value)
No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for STU:ZCY
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZCY has been successfully added to your 
